Carbapenem resistance in Escherichia coli is rare. We report four genetically unrelated carbapenem-resistant E. coli isolates cultured from four patients hospitalized in Tel Aviv Medical Center. PCR, sequencing, and Southern blot analysis identified KPC-2 as the imipenem-hydrolyzing enzyme in all four strains, carried on different plasmids with a possible common origin. This is the first discovery of KPC-2 in E. coli and the first report of this enzyme originating outside the United States.
with UV light. bla KPC-2 radioactively labeled with random-primer-DNA-labeling mixture (Biological Industries, Beit Haemek, Israel) was used as a probe.
RESULTS
Patients' background, antibiotic susceptibilities, and genetic relatedness. Carbapenem-resistant E. coli was initially identified at Tel Aviv Medical Center in February 2005 and was subsequently isolated from three additional patients during September and October 2005. This represents an incidence rate of 5.7 cases/100,000 admissions and a proportion of resistance to carbapenem among E. coli isolates of 0.15%. While these isolates were cultured from patients with different clinical backgrounds (Table 1) , they were all chronically ill, with extensive exposure to the medical system. Nevertheless, they were hospitalized in different wards and cared for by different staff members, and no common epidemiological link between them was identified. No apparent contact between the patients or travel to the east coast of the United States was documented.
PFGE revealed four different SpeI endonuclease-restricted DNA profiles, with band difference greater than seven, indicating that all four strains were genetically unrelated (18) . Three of the patients had recent antibiotic exposure, but only one was treated with carbapenems before E. coli was isolated.
All isolates were multidrug resistant, with different antibiotic susceptibilities ( Table 2 ). All strains were resistant to ertapenem, three were imipenem resistant and one imipenem intermediate, and three were meropenem resistant and one meropenem susceptible.
Detection of a carbapenem-hydrolyzing ␤-lactamase. Crude enzyme preparations of all four E. coli strains showed alterations in the shapes of the zones of inhibition around a susceptible E. coli test organism, indicating the production of a ␤-lactamase with imipenem hydrolysis activity. Phenotypic screening for metallo-␤-lactamase was negative in all four strains. IEF showed production of various ␤-lactamases (Fig.  1A , lanes D), with two distinct bands observed in all four strains migrating as bla TEM (pI 5.4) and a ␤-lactamase migrating with a pI of 6.7. Isolates 157 and 360 expressed two additional ␤-lactamases with pIs of 7.4 and above 9.0, and isolate 329 showed a ␤-lactamase with a pI of 7.9.
Analysis and transfer of KPC-2-encoding plasmid DNA. Plasmid DNA analysis of the E. coli strains revealed a different band pattern, with a plasmid of Ͼ85 kb in three of four strains (Fig. 1B) . Transformation of plasmid extracts into E. coli DH5␣ succeeded, and PCR on plasmid DNA isolated from transformed colonies followed by cloning and sequencing confirmed the presence of bla KPC-2 . ␤-lactamase extracts from all four transformants subjected to IEF showed one distinct band focusing at pI 6.7, corresponding to the pI of KPC-2 (2) ( resistant to imipenem or meropenem (Table 1) . Other PCRscreening reactions using specific primers for known class A carbapenemases were all negative. Plasmid analysis of all four transformants indicated that each had acquired a single plasmid (Fig. 1B, lanes T) , with the largest plasmid transferred from parent strain 157 (Fig. 1B,  lane 2) . Plasmids from strains 329 and 339 appeared similar in size (Fig. 1B, lanes 4 and 6, respectively) . Restriction analysis using various endonucleases (Fig. 1C) showed different restriction profiles, but clear similarities (BglII and EcoRV) and even identity (Sma) in the band patterns were noticeable, suggesting the possibility of a common origin. Strain 157 exhibited a unique restriction pattern (Fig. 1C) . Southern blot analysis using a bla KPC-2 probe following restriction with BglII, EcoRV, or SmaI, which digests bla KPC-2 at nucleotide 790, proved the presence of bla KPC-2 in the transferred plasmids (Fig. 1D) . Although KPC-2-encoding plasmids in the parent strains differed, hybridization was positive at the same position on the blot for each strain (hybridization results are presented only for strain 360 as a representative), supporting the possibility that the plasmids shared a large fragment that contained the gene.
DISCUSSION
Our study is the first to report on KPC-2 in E. coli clinical strains and the first to report KPC-2 outside the United States without an apparent U.S. origin. The enzyme was found in four genetically unrelated carbapenem-resistant isolates of E. coli from four epidemiologically unrelated patients. Three of the patients had been treated recently with antibiotics but only one with a carbapenem. The KPC-2 gene was carried on four different plasmids that contained a common encoding element and probably had a common origin.
Transfer of these plasmids to a susceptible E. coli strain increased the imipenem MIC significantly but did not confer complete resistance, suggesting that an additional mechanism is involved in carbapenem resistance in these strains. Among the possibilities for such a mechanism are porin alterations, which reduce the entry of carbapenems into the cell, as has been shown mainly for imipenem-resistant Klebsiella pneumoniae strains (9, 20) or efflux pumps, a mechanism more common in nonfermenters, such as Pseudomonas aeruginosa and Acinetobacter.
KPC-2 was originally identified in K. pneumoniae strains from Maryland in 2003 (13) , and since then, it has been identified in a Salmonella strain from the same area (12) , in an Enterobacter strain from Boston (8) , and in K. pneumoniae strains from New York (3). KPC class A ␤-lactamases have been reported to date only in the United States or as originating in the United States, as in the case of the Klebsiella pneumoniae strain in France that was likely acquired by a patient during hospitalization in New York (14) . Our study is the first to report KPC-2 outside the United States without an apparent U.S. origin. PFGE indicated that these E. coli strains were genetically unrelated. Epidemiological investigation revealed that two of the four clinical strains were not acquired in the hospital and were likely imported from two different chronic-healthcare facilities, posing the worrying problem of fluctuation of carbapenem resistance in and out of the hospital setting.
Carbapenem resistance in E. coli remains rare, and therefore, at present, there are no clinical outcome data on infections caused by these strains. In our cases, carbapenem treatment did not seem to be a prerequisite for the isolation of carbapenem-resistant E. coli. Nevertheless, the existence of the KPC-2 gene on plasmids that may carry additional antibiotic resistance determinants poses the possibility of dissemination of this carbapenem-encoding gene between and among species.
